Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Journal of Sun Yat-sen University(Medical Sciences)》 2013-03
Add to Favorite Get Latest Update

Efficacy and Safety of Toremifene in Young Patients with Luminal Subtype Early Breast Cancer: A Retrospective Study

QIN Tao,YUAN Zhong-yu,PENG Rou-jun,BAI Bing,SHI Yan-xia,TENG Xiao-yu,LIU Dong-geng,WANG Shu-sen*(Department of Medical Oncology,State Key Laboratory of Oncology in South China / / Cancer Center,Sun Yat-sen University,Guangzhou,510060,China)  
【Objective】 There is no study about toremifene in the treatment of young breast cancer patients.This study aimed to compare the efficacy and safety of toremifene for young premenopausal breast cancer patients.【Methods】 We retrospectively reviewed 247 young(≤35 years old) premenopausal Luminal type operable breast cancer patients,including 66 patients treated with toremifene and 181 patients treated with tamoxifen between January 2002 and October 2007.Survival was compared by Kaplan-Meier method with Log-rank test.Multivariate analysis was conducted by Cox hazard ratio regression model.【Results】 Median age for toremifene and tamoxifen were 33 years and 32 years,respectively.After median follow-up duration of 77.1 months,6-year diseasefree survival was not significantly different between tamoxifen and toremifene(77.0% vs 79.2%,respectively).Similarly,6-year overall survival was not significantly different between tamoxifen and toremifene(88.4% vs 87.4%,respectively).There was no difference between patients treated with toremifene versus tamoxifen in terms of overall survival(HR = 0.794;P = 0.589) and diseasefree survival(HR = 1.132;P = 0.686).Adverse events were similar in the two groups.Univariated analysis showed that tumor size,grade,stage and HER2 overexpression were associated with short disease-free survival.Progesterone receptor status might affect disease-free survival(P = 0.056).Lymphovascular invasion,positive lymph node and advanced stage predicted poor overall survival.Multivariate analysis showed that HER2 overexpression and progesterone receptor negative were associated with short disease-free survival.Advanced stage was a predictor for unfavorable overall survival.【Conclusion】 There was similar benefit in overall survival and disease-free survival in young premenopausal patients with operable breast cancer between patients receiving toremifene and tamoxifen.Further perspective clinical trials were needed to confirm the value of toremifene in adjuvant endocrine therapy for patients with premenopausal breast cancer.
【Fund】: 国家自然科学基金(81272896)
【CateGory Index】: R737.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【References】
Chinese Journal Full-text Database 2 Hits
1 Qu Hong-ying;Department of Medical Oncology, Baotou Medical College the First Affiliated Hospital;;Effect and safety of Toremifene treating young operable breast cancer[J];世界最新医学信息文摘;2015-A4
2 ZHANGHouyun;ZHAO Linyun;Department of Oncology,the Second People's Hospital of Kaifeng;;Recent advances in endocrine therapy for breast cancer[J];中国普通外科杂志;2014-05
【Co-references】
Chinese Journal Full-text Database 10 Hits
1 ZENG Yin-duo;XU Fei;QIN Tao;YANG Yan-hua;LIAO Yu-ting;QIN Ge;WANG Shu-sen;Center of Breast Tumor,Sun Yat-sen Memorial Hospital,Sun Yat-sen University;Cancer Center of Sun Yat-sen University,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University;;Toremifene in Postmenopausal Operable Patients with Luminal Subtype of Breast Cancer as Compared with Tamoxifen:A Retrospective Study in China[J];中国普外基础与临床杂志;2014-05
2 ZHANGHouyun;ZHAO Linyun;Department of Oncology,the Second People's Hospital of Kaifeng;;Recent advances in endocrine therapy for breast cancer[J];中国普通外科杂志;2014-05
3 LUO Xiang,SHI Yanxia,JIANG Wenqi,LI Zhiming,CAI Yuchen.Department of Medical Oncology,Pingxiang People's Hospital,Pingxiang 337000,China;The inhibitory effects and mechanisms of flutamide on human breast cancer cell line HCC1937[J];临床肿瘤学杂志;2013-07
4 QIN Tao,YUAN Zhong-yu,PENG Rou-jun,BAI Bing,SHI Yan-xia,TENG Xiao-yu,LIU Dong-geng,WANG Shu-sen*(Department of Medical Oncology,State Key Laboratory of Oncology in South China / / Cancer Center,Sun Yat-sen University,Guangzhou,510060,China);Efficacy and Safety of Toremifene in Young Patients with Luminal Subtype Early Breast Cancer: A Retrospective Study[J];中山大学学报(医学科学版);2013-03
5 DAI Ying1,FU Jing2,WEI Bing1,HE Du1,ZHANG Hong-ying1,BU Hong1(1Department of Pathology,West China Hospital,Sichuan University,Chengdu 610041,China;2Department of Pathology,Sichuan Provincial People's Hospital,Chengdu 610072,China);Prognostic significance of positive rate and staining intensity of ER and PR in tamoxifen-treated patients with invasive breast carcinoma[J];临床与实验病理学杂志;2013-04
6 JIANG Hang1,2,WANG Tao2,ZHANG Shao-hua2,DU Meng2,WU Shi-kai2,SONG San-tai2,JIANG Ze-fei2(1.Medical School of Chinese PLA,Beijing 100853,China;2.Department of Breast Oncology,307 Hospital of PLA,Beijing100071,China);Fulvestrant for the treatment of advanced breast cancer after prior aromatase inhibitor therapy[J];中国癌症杂志;2013-03
7 YANG Jun-lan,YOU Jun-hao,HAN Chun,LINGHU Rui-xia,ZHU Yan-yun,FANG Ping Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China;Therapeutic effect of fulvestrant on estrogen receptor–positive advanced breast cancer[J];解放军医学院学报;2013-04
8 FAN Jia-zuan, YANG Zheng-yu, ZENG Tao (Department of Pharmacy, Obstetrics & Gynecology Hospital, Fudan University, Shanghai 200090, China);The effects of gonadotropin-releasing hormone analogues on breast cancer and ovarian function protection[J];上海医药;2012-19
9 LIU Qian~*,WANG Tao,JIANG Ze-fei,ZENG Min, ZHANG Shao-hua,WU Shi-kai.*Chinese PLA Postgraduate Medical School,Beijingl00071,China;Clinical research of medical ovarian suppression combined with anastrozole in the treatment of metastatic breast cancer in premenopausal women[J];肿瘤研究与临床;2012-06
10 MA Da-chang,WU Duo-ming,XIAO Yi, WANG Hong-lei,WU Li (Department of Breast,First hospital of Lanzhou University,Lanzhou 730000,China);A Meta analysis of toremifene comparison tamoxifen for early stage breast cancer[J];兰州大学学报(医学版);2012-02
【Secondary References】
Chinese Journal Full-text Database 5 Hits
1 Qu Hong-ying;Department of Medical Oncology, Baotou Medical College the First Affiliated Hospital;;Effect and safety of Toremifene treating young operable breast cancer[J];世界最新医学信息文摘;2015-A4
2 YANG Qiaolu;ZHANG Zhiming;First Affiliated Hospital of Xiamen University,Breast Surgery;;Exemestane and Tamoxifen Combined With Ovarian Inhibitors in the Treatment of Breast Cancer to Compare the Value of Premenopausal Women[J];中国卫生标准管理;2015-30
3 LI Dandan;Department of Surgery,Changzhou First People's Hospital;;Relations of levels of endogenous sex hormones and blood lipids with breast cancer in postmenopausal women[J];中国普通外科杂志;2015-05
4 LONG Jianping;MA Xiufen;MAO Hongyan;DU Xiaoyan;First Department of Breast,Maternal and Child Health Hospital of Gansu;;Efficacy and safety of third generation aromatase inhibitors in postmenopausal women with breast cancer:a Meta-analysis[J];疑难病杂志;2015-04
5 LIU Cai-gang;LI Xue-lu;MA Zhen-hai;Department of Breast Surgery,the Second Affiliated Hospital of Dalian Medical University;;Status and Application of Advanced Breast Cancer in the Adjuvant Treatment[J];医学与哲学(B);2014-08
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved